A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

Beyfortus is usually given by a healthcare provider in a hospital, clinic, or pediatrician’s office. Your child’s healthcare provider will make sure your child is receiving Beyfortus as scheduled.

Sanofi is pleased to announce Beyfortus® (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration of this ...

When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.

Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs . Late-breaking data show infant respiratory syncytial virus (RSV) ...

Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs . Late-breaking data show infant respiratory syncytial virus (RSV) ...

Investing.com -- Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales ...

Across all clinical endpoints, a single dose of Beyfortus delivered consistent and sustained efficacy against RSV disease vs placebo Beyfortus is the first preventive option approved to protect a ...

Beyfortus® is the first long-acting antibody approved in Canada for the prevention of RSV lower respiratory tract disease in newborns and infants through their first RSV season.ii As RSV ...